Skip to Main Content

Paper Details

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
J Thorac Oncol
6
2023
Advanced NSCLC, Bintrafusp alfa, PD-L1, Patients, Pembrolizumab, Programmed Death-Ligand 1, Solid Tumors, TGF- ", advanced NSCLC, bintrafusp alfa, human, human immunoglobulin G1 monoclonal antibody, patients, pembrolizumab, programmed death-ligand 1
Author NameAffiliation
Edward B GaronDavid Geffen School of Medicine, University of California, Los Angeles (university of california los angeles)
Edward B GaronDavid Geffen School of Medicine, University of California, Los Angeles (university of california los angeles)
  • 1 - 2

Datasets

Release 1.2